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Preventive clinical triala b s t r a c t
Summary: Trial Design: An interventional, phase 4, single group assignment, without masking (open
label), preventive clinical trial was carried out in health workers with biological risk in their tasks,
who have been filed as non-responders to conventional vaccination against Hepatitis B.
Methods: 67 health workers with biological risk in their tasks, who have been filed as non-responders to
conventional vaccination against Hepatitis B, were enrolled in the Clinical Trial. All participants were
from 18 years up to 64 years old. Inclusion Criteria: NHS workers -including university students doing
their internships in health centres dependent on the National Health System (inclusion of students is reg-
ulated and limited by specific instructions on labour prevention in each autonomous community)- clas-
sified as non-responders. The criteria defining them as non-responders to the conventional hepatitis B
vaccine is anti HBsAb titers < 10 mUI/ml following the application of six doses of conventional vaccine
at 20 lg doses (two complete guidelines). The objective of this study was to provide Health workers-
staff with an additional protection tool against hepatitis B infection, and to evaluate the efficacy of the
adjuvanted vaccine in healthy non-responders to conventional hepatitis B vaccine. The primary outcome
was the measurement of antibody antiHBs before the first Fendrix dose and a month after the admin-
istration of each dose. Other outcome was collection of adverse effects during administration and all
those that could be related to the vaccine and that occur within 30 days after each dose. In this study,
only one group was assigned. There was no randomization or masking.
Results: The participants were recruited between April 13, 2018 and October 31, 2019. 67 participants
were enrolled in the Clinical Trial and included the analyses. The primary immunisation consists of 4 sep-
arate 0.5 ml doses of Fendrix, administered at the following schedule: 1 month, 2 months and 6 months
from the date of the first dose. Once the positivity was reached in any of the doses, the participant fin-
ished the study and was not given the following doses. 68.66% (46 out 67) had a positive response to first
José L. Bravo-Grande, M. Asunción Blanco-González, José M. de la Torre-Robles et al. Vaccine 39 (2021) 554–563dose of Fendrix. 57.14% (12 out 21) had a positive response to second dose of Fendrix. 22.22% (2 out 9)
had a positive response to third dose of Fendrix and 42.96% (3 out 7) had a positive response to last dose
of Fendrix. Overall, 94.02% (64 out 67) of participants had a positive response to Fendrix. No serious
adverse event occurred.
Conclusions: The use of Fendrix, is a viable vaccine alternative for NHS workers classified as ‘‘non-
responders”. Revaccination of healthy non-responders with Fendrix, resulted in very high proportions
of responders without adverse events.
Trial registration: The trial was registered in the Spanish National Trial Register (REEC),
ClinicalTrials.gov and inclusion has been stopped (identifier NCT03410953; EudraCT-number 2016-
004991-23).
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1.1. Scientific background and rationale
Independently of the current pandemic, working in health care
entails exposure to numerous inherently associated risks even
under normal circumstances. These include several biological risks
which may vary widely according to the cases in question. One
example is hepatitis B, which continues to cause many deaths
worldwide.
Hepatitis B is the most serious type of viral hepatitis. It was first
identified in 1963 by Blumberg, a US scientist. While analysing
blood samples from populations around the world, he discovered
the hepatitis B surface antigen in a sample from an Australian abo-
rigine, hence he initially called it the Australian antigen. This laid
the foundation for the study of a recently identified disease that
had been known since ancient times as epidemic or catarrhal
icterus [1–6]. Almost 20 years then passed until in 1981, the same
Blumberg succeeded in obtaining a vaccine that was 95% effective
against hepatitis B [7], followed by almost another decade of inten-
sive vaccination campaigns until in 1991, the incidence of hepatitis
B had fallen by approximately 82% in the United States [7–10].
Universal vaccination against this microorganism in children
has improved in most developed countries. The vaccine has proved
effective in reducing not only cases but also the long-term conse-
quences of hepatitis B, such as chronic hepatitis, cirrhosis and hep-
atocellular carcinoma [2,6,9–12].
It is estimated that there are 250 million hepatitis B carriers in
the world and that the virus kills about 900,000 people every year.
According to the latest data from the European Union, the 25–44
age group presents the highest rate of new infections, followed
by those aged 15–24. Prevalence in Europe ranges between 0.1%
in Ireland and 4.4% in Romania. Spain is one of the countries with
a low endemicity of hepatitis B, presenting a cumulative preva-
lence of HB surface antigen (HBsAg) carriers of 0.8% [13]. In
2016, there were 530 cases of hepatitis B in Spain and the resulting
incidence was 1.14 cases per 100,000 inhabitants. Due to its
chronic nature, hepatitis B represents a major public health prob-
lem, not only because of its associated morbidity and mortality
but also and fundamentally because HBsAg carriers constitute
the main reservoir of the virus.
Although the vaccine is effective in 95% of individuals, no stud-
ies have been conducted to determine whether it remains effective
after 10 years or if a booster is required. An American research
team monitored 1578 individuals in Alaska (United States) who555received three doses of the hepatitis B vaccine between 1981 and
1982 [14]. Fifteen years after vaccination, the team tested all sub-
jects for antibodies that would protect them from infection and
found that the number of antibodies against the virus had fallen
since vaccination. The factors associated with a greater likelihood
of continuing to present high antibody levels at 15 years were:
being male, being older at the time of vaccination and having
developed a high number of antibodies at the start [8–10,14–24].
In this regard, the study by Bruce et al. [17] provides wide-
spread evidence that humoral immunity persists for 30 years,
however, it requires studies to determine the state of cell-
mediated immunity would be complementary and important,
especially in those who lose anti-HBs and do not respond to a boos-
ter dose.
Although any individual without immunity to the hepatitis B
virus (HBV) is susceptible to the disease, some groups are at
greater risk due to high-risk practices, illness or simply personal
contact. Health care staff comprise one of these groups, with a 2–
10 times higher risk of infection than the general population.
Transmission generally occurs through accidental exposure to
patients’ blood, primarily as a result of parenteral procedures
[3,11,18,20,25].
Since 5% of the general population does not respond to the con-
ventional vaccine, and because antibody levels decrease over time,
seroprotection against the virus remains uncertain. Therefore, it is
necessary to find an alternative to protect health service staff who
do not have antibodies, either because they never generated a
response or because they no longer respond to the conventional
vaccine. Fendrix, the hepatitis B vaccine formulated with the
new AS04 adjuvant (MPL + aluminum salts) by GlaxoSmithKline,
may provide a good alternative [19,26–28]. The vaccine is indi-
cated for patients with renal insufficiency, especially those on
hemodialysis and pre-hemodialysis aged over 15 years old
[19,22,28–35]. It has been reported that revaccination with Fen-
drix has a high success rate in HIV patients who do not respond
to other vaccination strategies against hepatitis B [30,34–35].
Compared with the conventional vaccine, the additional costs of
administering Fendrix to health service staff as a prophylactic
against hepatitis B are more than justified if we consider the mean
costs entailed in monitoring and treating hepatitis B in health ser-
vice staff infected through accidental exposure [36,37], combined
with the associated sick leave [38–39]. In addition, in the case of
accidental infection, the cost of a reported occupational accident
would be lower in immunised than in non-immunised subjects
[40].
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 Objectives
o To endow Spanish Health Service staff with additional pro-
tection against hepatitis B infection.
o To assess the efficacy of the adjuvanted vaccine in healthy
subjects who do not respond to the conventional hepatitis
B vaccine.
 Hypothesis
o Administration of the Fendrix vaccine is a viable alternative
for Spanish Health Service staff classified as ‘‘non-
responders”.
2. Methods
2.1. Clinical study design
2.1.1. Description of the clinical study design
We conducted a non-randomised, multi-centre, phase 4 clinical
trial with a single group, without masking (open-label), adminis-
tering medication for off-label use in Spanish Health Service staff
whose work exposed them to biological risk and who had been
classified as non-responders to the conventional hepatitis B
vaccine.
2.1.2. Significant changes in the methods after initiating the trial
The main changes in this clinical trial concerned subject recruit-
ment. As the initial rate of recruitment was lower than expected,
we prolonged the recruitment time. This change modified overall
study length and the dates of the trail stages. For similar reasons,
we expanded our study population from the Autonomous Commu-
nity of Castile-Leon Health Service (Spanish initials: SACYL) to the
Spanish Health Service (Spanish initials: SNS) to enable inclusion of
centres outside the Autonomous Community of Castile-Leon
(Spanish initials: CyL). This led to the inclusion of 6 centres from
the autonomous community of Madrid. Lastly, to further facilitate
recruitment, the inclusion criteria were modified to include health
sciences students undertaking a work placement with the SNS.
This inclusion of students was subject to and limited by the specific
regulations on health and safety in each autonomous region.
This clinical study was approved by the medical research ethics
committee at the University Hospital of Salamanca on 25 Septem-
ber 2017, for implementation at the participating centres (ref.
17/1311), and was authorised by the Spanish Agency for Medicines
and Health Products (Spanish initials: AEMPS) on 16 October 2017
(EudraCT number: 2016-004991-23) for implementation in these
hospitals. (For protocol see https://clinicaltrials.gov/ct2/show/
NCT03410953).
2.2. Participants
2.2.1. Participant selection criteria
In order to be recruited for this clinical trial, subjects had to
work in the SNS —including university students undertaking work
placements in SNS health centres (subject to and limited by the
specific regulations on health and safety in each autonomous
region)— and be of working age. In addition, they had to be free
of any condition that contraindicated vaccination with Fendrix.
They also had to meet the criteria for classification as a non-
responder to the conventional hepatitis B vaccine: anti-HBs anti-
body titers of <10 mIU/ml following administration of six 20 lg
doses of conventional vaccine (two complete series). All subjects
signed an informed consent form.
The exclusion criteria were as follows: known allergy to the
active ingredient or to any other of the drug components (included
in section 6 of the summary of product characteristics); a past556allergic reaction to any hepatitis B vaccine; or presenting a serious
infection with fever at the time of recruitment. Subjects who did
not give their informed consent were also excluded.
2.2.2. Site (centres and institutions) where data were collected
Eleven SNS hospitals participated in this clinical trial, and these
are listed below:
 Complejo Asistencial Universitario de Salamanca. (Coordinating
Center)
 Hospital Clínico Universitario de Valladolid
 Complejo Asistencial de Zamora
 Complejo Asistencial Universitario de León
 Complejo Asistencial Universitario de Palencia
 Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Madrid.
 Hospital Clínico San Carlos, Madrid.
 Hospital Universitario 12 de Octubre, Madrid.
 Hospital Universitario Gregorio Marañón, Madrid.
 Hospital Universitario Puerta de Hierro, Madrid.
 Hospital Universitario Ramón y Cajal, Madrid.
2.3. Interventions
Fendrix is a hepatitis B vaccine that contains the HBsAg adju-
vant (3-O-desacyl-40-monophosphoryl lipid A and aluminum phos-
phate). This adjuvant system is known as AS04 and it boosts
vaccine immunogenicity. An anti-HB antibody titre of 10 mIU/
ml correlates with protection against HBV infection.
Immunization consisted of a maximum of four 0.5 ml doses of
Fendrix administered as follows: 1, 2 and 6 months after the date
of the first dose, by intramuscular injection of a 20 mg dose in the
deltoid muscle, as indicated in the Fendrix summary of product
characteristics. We conducted a serological analysis about 30 days
after administration of each dose. If subjects presented seroprotec-
tion (anti-HB  10 mIU/ml), administration of subsequent doses
was suspended.
The Fendrix vaccine lots used in this trial were: AFENA027BC
(01/2020), AFENA028AI (05/2020) and AFENA029AC (09/2020).
We observed precautionary measures as regards the product
contraindications and warnings indicated by the manufacturer
and AEMPS recommendations for off-label use.
Thirty days after administration of each vaccine dose, we took a
venous blood sample to determine anti-HBs titres. Serum samples
were analysed immediately in the certified reference laboratory at
each participating hospital, extracting the sample according to
each laboratory’s technical instructions. Anti-HBs values above
1000 mIU/ml were assigned a value of 1000 mIU/ml. The lower
limit of detection for the trial was 3 mIU/ml. All values below
the lower limit of detection were assigned a value of 3 mIU/ml.
Adverse effects were recorded during vaccine administration,
noting all those that could be related to the vaccine and had
appeared in the 30 days following each dose.
2.3.1. Results
After measuring the anti-HBs antibody titre before the first dose
and one month after administration of each dose, the results for
anti-HBs antibody titres were analysed to determine immune
response to the adjuvanted vaccine. Anti-HBs titres greater than
or equal to 10 mIU/ml were classified as positive.
To assess results for adjuvanted vaccine safety and clinical tol-
erance, adverse effects were recorded during administration, not-
ing all those that could be related to the vaccine and had
appeared within 30 days after each dose.
As secondary objectives, we analysed biochemical data col-
lected immediately prior to administering the first vaccine to
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ber of doses necessary to achieve a positive response. In addition,
we analysed the influence of sex and age on the results.
2.3.2. Sample size
The total number of staff at the 11 centres participating in this
clinical trial was approximately 47,650 at the time of conducting
the trial. In an analysis that included 2620 eligible adults who
had participated in 11 studies conducted in 10 countries, Van
Der Meeren [41] described a 94.5% response rate to the conven-
tional vaccine. Consequently, we estimated a target population
for our trial of 2621 subjects. Raheja and colleagues [42] have indi-
cated that for various reasons, about one-third of workers will
refuse to participate in this type of trial, which would reduce our
target population to 1730.
A literature review indicated that the mean percentage of work-
ers who do not respond to the Fendrix vaccine ranges from below
1% to 10% [7,15,19,29,32,35]. This would noticeably affect sample
size calculation. Taking 5% as the mean percentage of workers
who do not respond to Fendrix and assuming an error margin
of ±1%, we required 70 subjects in total, with a range of 57–83,
in order to achieve a 95% confidence level with a maximum accept-
able error margin of 5%.
2.3.3. Randomization and masking
This was an open clinical trial without control group or
masking.
2.3.4. Statistical analysis
We used two statistical methods to compare groups:
When both the variable of interest and the secondary variables
were qualitative, we entered them into contingency tables and
used Fisher’s exact test to determine any dependency between
both variables.
When the variable of interest was numeric and the secondary
variables were qualitative, we used the Wilcoxon rank-sum test,
since numeric variables do not generally come from normally dis-
tributed populations and therefore the classic parametric tests are-
not recommended. We used the Shapiro-Wilks test to determine
normality, due to its higher power compared to other similar tests
[43].
In all analyses, we eliminated missing values.
To describe the qualitative variables, we used frequency tables
and bar graphs, obtaining confidence intervals for the first category
of each variable.
Means and standard deviations were used to describe numeric
variables, but also quartiles, due to the absence of normality, both
globally and by category for some qualitative variables. We also
estimated confidence intervals for the population mean of each
variable, assuming unknown variance.
In addition, we calculated Spearman correlations for numeric
variables to determine dependency between them. Once again, a
non-parametric method was used due to the absence of normality.3. Results
3.1. Participant flow chart
3.1.1. Recruitment
3.1.1.1. Dates that define the periods of recruitment and follow-
up. From 26 April 2018, the date of the inclusion of the first sub-
ject, to 11 June 2019, the date of the inclusion of the last subject,
94 individuals were assessed for eligibility, of whom 67 were
included in the present study (Fig. 1). Follow-up continued until
31 October 2019.557On 14 November 2019, the trial was concluded with 67
recruited subjects. Of the 94 subjects assessed for eligibility, 27
did not agree to participate in the trial and declined to sign an
informed consent form.
In the absence of losses or exclusions, data analysis was con-
ducted with 67 subjects.
3.1.2. Baseline data
3.1.2.1. Baseline demographic and clinical characteristics. The possi-
ble factors that could alter our primary result (e.g. age, baseline
anti-HBs titre, diabetes, body mass index) were in line with those
of a normal healthy population of non-responders to the conven-
tional vaccine (Table 1, Table Anx1 and Table Anx2), with the
exception of sex, whereby the population presented a marked shift
towards women, reflecting the current composition of the health
worker population in the Spanish Health Service.
3.1.3. Numbers analysed
As described in the interventions section, the vaccine was only
administered to subjects whose previous serology was negative.
Thus, the first dose was administered to 67 subjects, the second
dose to 21 subjects, the third to 9 subjects and the fourth to 7
subjects.
3.1.3.1. Distribution of numeric variables. We used the Shapiro-
Wilks test [43] to determine whether any of the numeric variables
comes from a normal distribution (Gaussian). The hypotheses
were:
 H0: the sample variable comes from a normally distributed
population
 H1: the sample variable does not come from a normally dis-
tributed population
Most of the numeric variables (except ‘‘height” and ‘‘crea-
tinine”) did not present a normal distribution, with a significance
of 5e02 (0.05) (see Table 2).
3.1.4. Results and estimation
Of the 67 subjects participating in this trial, 63 (94.03%)
attained anti-HBs levels of 10 mIU/ml, indicating seroprotection
against HBV (Table 3).
A cumulative analysis of the response data indicated a gradual
increase in subjects reaching seroprotection: 68.66% with the first
dose, 86.57% with the second dose, 89.55% with the third dose and
94.03% with the fourth dose (Fig. 2).
We did not detect any serious adverse effects during this clini-
cal trial. Most of the adverse effects observed occurred after
administering the first dose. Some 30% of vaccinations (32 out of
104) gave rise to adverse effects, and of these, 78.12% were related
to the medication under study (Table 4). The symptoms were tran-
sient and almost all resolved spontaneously within 1 week.
By symptom, the most common effect (59.38%) was pain at the
injection site. Seven adverse effects were not associated with the
medication, and the most common of these was ‘‘malaise”. Table 4
gives all the data obtained on adverse effects.
3.1.5. Secondary analysis
We found a relationship between sex and response to the first
vaccine dose. This was determined by performing the Wilcoxon
rank-sum test with continuity correction, where the hypotheses
to test were H0: Anti-HBs (men)  Anti-HBs (women) and H1:
Anti-HBs (men) < Anti-HBs (women). The test yielded a p-value
of 0.037 (W = 318.5), which is lower than 0.05, thus H0 is rejected
and H1 accepted, indicating that men presented a lower level of
Anti-HBs (Fig. 3).
Fig. 1. Flow chart.
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tered, probably because of the low ‘‘n” when these doses were
administered. This effect has been described previously for other
hepatitis B vaccines. [20,44]
Table 5 shows the quantitativevariables that present significant
differences by the sex categories. In all the variables, except558‘‘AntihHbS visit 2”, the values in male are significantly higher than
in female.
3.1.5.1. Spearman correlation matrix. We found the following signif-
icant correlations (p-value  0.05) as shown in Fig. Anx1:
 Age and Glucose, Urea, GGT, Visit_2_AntiHbS.
Table 1
Demographic and clinical baseline characteristics.
Number of subjects
Age group Male Female Total
18–40 years 3 11 14
40–80 years 17 36 53
Global 20 47 67
mean sd IQR 25% 50% 75% n NA
Age 49,46 11,77 14 43 53 57 67 0
Female 47,95 11,43 11,00 42 52 55 47 0
Male 53,00 12,07 20,75 44 58 62 20 0
Weight (kg) 71,67 15,73 21,25 59,3 70,0 80,5 66 1
Female 65,90 11,99 15,12 56,6 63,5 71,8 46 1
Male 84,93 14,48 16,27 74,1 80,0 90,3 20 0
Height (cm) 166,72 8,17 9,50 161,50 166,00 171,00 67 0
Female 162,70 5,12 6,50 160 163 166 47 0
Male 176,15 5,91 10,00 171 177 181 20 0
Glucose Urea Uric Ac. ALT-GPT AST-GOT GGT Bilirubin Creatinine Anti HbS
% n % n % n % n % n % n % n % n % n
Normal 92,64 62 95,31 61 88,06 59 95,38 62 96,72 59 87,88 58 93,85 61 92,54 62 0 0
Abnormal 7,46 5 4,69 3 11,94 8 4,62 3 3,28 2 12,12 8 6,15 4 7,46 5 100 67
Table 2





Selection Visit AntiHbS 2.611177e-15
Selection Visit Glucose 1.172472e-02
Selection Visit Uric Acid 3.507400e-02
Selection Visit Urea 1.281404e-02
Selection Visit Creatinine 1.598279e-01
Selection Visit Bilirubin 8.114063e-10
Selection Visit AST_GOT 4.851082e-11
Selection Visit ALT_GPT 1.844211e-11




Final visit AntiHbS 1.000965e-05
Consequently, we used non-parametric tests with these
variables to test other associated hypotheses.
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Creatinine, ALT_GPT, GGT.
 Height and Uric acid, Creatinine, Bilirubin.
 Glucose and Uric acid, GGT.
 Uric Acid and ALT_GPT, GGT.
 Urea and Creatinine.
 Creatinine and GGT
 AST_GOT and ALT_GPT.
 ALT_GPT and GGT, Visit_2_AntiHbS.
 GGT and Visit_2_AntiHbS.
 Visit_3_AntiHbS and Visit_4_AntiHbS.Table 3







559We also analysed the influence of age on vaccine response and
observed a significant correlation (r = 0.37 with p-value = 0.0019)
between age and response to the first dose. This finding indicates
an inverse correlation between variables, whereby the higher the
age, the lower the response (Fig. 4). This effect was not observed
for the following doses administered, probably because of the
low ‘‘n” when these doses were administered.3.1.5.2. Contingency tables and test of independence. To study depen-
dence between two qualitative variables, we performed Fisher’s
exact test, where the hypotheses were:
o H0: Variables are independent
o H1: Variables are dependent
The most relevant pair of variables that yielded a significant p-
value was:
 ‘‘Anti-HBs visit 2” and ‘‘Adverse effects visit 2”, p-
value = 0.0005149.
This indicates that the adverse effects reported following
administration of the first dose appear to be linked to not attaining
seroprotection (Fig. 5). This effect was not observed for the follow-
ing doses administered, probably because of the low ‘‘n” when
these doses were administered.
No relationship was found between the biochemical parameters
analysed –glucose, uric acid, urea, creatinine, bilirubin, AST-GOT,
ALT-GPT and GGT– and the response to vaccination with Fendrix.3.1.5.3. Influence of the time between the last dose of conventional
vaccine and revaccination with Fendrix on the response to vaccina-






Fig. 2. Cumulative response to vaccination. Cumulative percentage of individuals responding to the vaccine after each dose. After the first and second doses, a very high
percentage of positive response to the vaccine is achieved.
Table 4
Adverse Events (AE) found during the trial.
Dose 1 Dose 2 Dose 3 Dose 4 Total n Overall %
% n % n % n % n
Subjects with AE 31,30 21 28,57 6 11,11 1 14,28 1
Detected AE 24 6 1 1 32
Related to Medication
Yes 76,20 19 83,33 5 100,00 1 0,00 0 25 78.12
No 23,80 5 13,66 1 0,00 0 100,00 1 7 21.87
Type
Puncture Zone Pain 58,33 14 66,67 4 100,00 1 0,00 0 19 59,38
Discomfort 12,50 3 16,67 1 0,00 0 0,00 0 4 12,50
Fatigue 12,50 3 0,00 0 0,00 0 0,00 0 3 9,38
Diarrhea 8,33 2 0,00 0 0,00 0 0,00 0 2 6,25
Paresthesia in the puncture area 8,33 2 0,00 0 0,00 0 0,00 0 2 6,25
Cramp 0,00 0 16,67 1 0,00 0 0,00 0 1 3,13
Diverticulitis 0,00 0 0,00 0 0,00 0 100,00 1 1 3,13
Fig. 3. Response to the first dose of vaccine; comparative by sex. Boxplot of the
distributions by sex of ’AntiHbS after dose 1’ where we observe that males present
lower values and with less dispersion than females.
Table 5




Weight (kg) 789,5 4,39E-06
Height (Cm) 909,5 1,71E-09
Uric acid (mg/dL) 751 1,20E-04
Urea (mg/dL) 521 2,40E-02
Creatinine (mg/dL) 874 3,19E-08
Bilirubin (mg/dL) 620,5 1,50E-02
AST-GOT (U/L) 566 1,60E-02
ALT-GPT (U/L) 649 4,70E-03
GGT (U/L) 690,5 1,30E-03
AntiHbS Visit 2 (mUI/ml) 318,5 3,70E-02
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560study vaccination with the conventional vaccine and vaccination
with Fendrix for the trial. We do not see any relationship between
the time between vaccines and the response to vaccination with
Fendrix. Analyzing the final response to Fendrix, we find two very
unbalanced groups, to which after applying ‘‘Wilcoxon rank sum
test with continuity correction” we obtain W = 144 and p-value
Fig. 4. Response to the first dose of vaccine; Influence of age. Scatterplot between
’age’ and ’AntiHbS after dose 1’ showing that low levels of AntiHbS are mainly
concentrated in individuals aged between 50 and 60 years.
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(Fig. Anx2).
Analyzing the initial response to Fendrix, we find two more bal-
anced groups, to which after applying ‘‘Wilcoxon rank sum exact
test” we obtain W = 540 and p-value = 0.3592, not showing signif-
icant differences between the two groups (Fig. Anx3).3.1.5.4. Dependence between response and other factors. Finally, we
analyzed whether any immunosuppressive conditions, such as
the use of steroids or immunosuppressive diseases, or whether
previous or current pathologies, or if the concomitant medication
in the study had any influence on the response to revaccination
with Fendrix. These data were analyzed with the total response
to vaccination and the response to the first dose of Fendrix.Fig. 5. Relationship between the presence of Adverse Events after the first dose administe
dose 1’ and ’Presence of adverse events’ showing that individuals with abnormal values
561The only relevant data resulting from the analysis carried out is
that there is a dependency between ‘‘Global response” and ‘‘Possi-
ble conditioning pathology -YES/NO-” (p-value = 0.0063)
(Fig. Anx4) and between ’Global response’ and ‘‘Concomitant med-
ication -YES/NO- ”(p-value = 0.0092) (Fig. Anx5).
There are insufficient data to determine whether these associa-
tions are due to a specific pathology or to a specific drug.
3.1.6. Adverse effects (risk)
The 67 participants reported 32 adverse effects (AEs), of which
25 were adverse reaction (AR). None of the adverse effects reported
were considered serious and all patients recovered from their cor-
responding adverse effect, suggesting a low risk of serious adverse
effects and an acceptable risk in relation to non-serious adverse
effects, which corresponded to those already identified in the Tech-
nical Data Sheet.
Four subjects had diabetes mellitus type 2 prior to participating
in the trial. Van Der Meeren et al. [45] reported that the reacto-
genicity and safety profile of the hepatitis B vaccine (Engerix-
BTM) appeared similar in controls and patients with hepatitis B
and was consistent with the experience of the vaccine). Two of
them did not reach a response after 4 doses of Fendrix and the
others attained seroprotection after the fourth dose. Another
non-responder had autoimmune hepatitis prior to participating
in the trial and the last non-responder did not present any patholo-
gies of interest.
3.1.6.1. Risk-benefit assessment. An analysis of the results revealed
no evidence of significant, identifiable or potential risks related
to administration of Fendrix in the study population (health ser-
vice staff and university students whose work in the SNS exposed
them to biological risk and who had been classified as non-
responders to the hepatitis B vaccine), beyond those already indi-
cated in the Technical Data Sheet.
3.1.7. Discussion
3.1.7.1. Limitations. Conducting the clinical trial in accordance with
the instructions of the Spanish Agency for Medicines and Health
Products (AEMPS) generated a slight difficulty. The AEMPS has
ruled that Fendrix should be administered as described in the
summary of product characteristics. Our trial observed these spec-red and acquisition of seroprotection (10 mIU/ml). Barplot between ’AntiHbS after
of ’AntiHbs after dose 1’ had adverse events.
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However, this limitation endowed our trial with added value.
One of the greatest difficulties we encountered while conduct-
ing this trial was recruitment, as samples from all hospitals were
small. This resulted in the need to extend recruitment to additional
centres in order to obtain an optimal study sample.
We also encountered a lack of information concerning staff who
do not respond to vaccination. The exclusion of the Fendrix vac-
cine for off-label use, or recent approval for use in patients with
immunodeficiency, diverts attention away from non-responder
staff. Consequently, treatment with specific immunoglobulin
remains the only possible option to treat a worker potentially
infected with the hepatitis B virus, despite the existence of a much
better alternative: the Fendrix vaccine.
Lastly, we also encountered some isolated difficulties as regards
organizing all trial visits and their dates for various reasons, includ-
ing vacations and sick leave. Although this posed an added diffi-
culty, it was resolved through study coordination.3.1.7.2. Extrapolation. The off-label use of Fendrix described here
will enable its administration to many potential beneficiaries if
the AEMPS approves such off-label use. These include:
o Health service staff
o Non-health service staff
o Employees in workplaces related to health care
o State security forces
o Prison officers
Our results pave the way for replicating the trial in other
countries.3.1.7.3. Interpretation. From the perspective of health, Fendrix
represents a viable alternative vaccine for SNS staff classified as
‘‘non-responders”.
As regards costs, according to previous publications, the ‘‘cost”
of the vaccine is offset by savings in:
 The cost of follow-up after a biological accident.
 The cost of administering specific immunoglobulin.
 The personal cost to the worker concerned.
 The level of response to a single dose.
Other information.
Trial registration: The trial was registered in the Spanish
National Trial Register (REEC), ClinicalTrials.gov and inclusion has
been stopped (identifier NCT03410953; EudraCT-number 2016–
004991-23).
Protocol: For protocol see https://clinicaltrials.gov/ct2/show/
NCT03410953
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